Clinical Trials Browser

Phase 1/2 × WW Domain-Containing Oxidoreductase × 90 days × Clear all

NCT07229638 2026-03-12

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor